Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Breast Neoplasms 3Neurotoxicity Syndromes 1Heart Failure 1Cardiotoxicity 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 266Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 146Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Carnitine × Breast × Clear all
NCT00247975 2022-08-16

Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Ottawa Heart Institute Research Corporation

Phase 2/3 Terminated
36 enrolled
Breast

Breast Neoplasms, Heart Failure

NCT04434404 2020-06-16

Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy

Horus University

Phase 4 Completed
83 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT00754767 2017-09-11

L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer

HealthPartners Institute

Phase 4 Terminated
2 enrolled 3 charts
Breast

Breast Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡